NRX Pharmaceuticals (NRXP) vs Tonix Pharmaceuticals (TNXP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
NRX Pharmaceuticals (NRXP) has outperformed Tonix Pharmaceuticals (TNXP) over the past year, losing 19.3% versus a loss of 67.6%. Over five years, NRXP leads with a -97.2% price change compared with -100.0% for TNXP. Tonix Pharmaceuticals is the larger company by market cap ($125.4 million vs $122.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NRXP | TNXP |
|---|---|---|
| Share price | $2.83 | $7.31 |
| Market cap | $122.53M | $125.37M |
| 1-day change | -2.08% | +0.41% |
| YTD return | +6.64% | -53.39% |
| 1-year return | -19.27% | -67.63% |
| 5-year return | -97.18% | -100.00% |
| EPS (TTM) | $-0.58 | $-13.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.06 | $22.38 |
| 52-week low | $1.62 | $7.10 |
| Distance from 52-week high | -44.02% | -67.34% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1260.42% | +508.76% |
| Average volume | 865.49K | 542.97K |
| Shares outstanding | 43.30M | 17.15M |
| Employees | 29 | 142 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRXP has outperformed TNXP by 48.4 percentage points over the past year.
About NRX Pharmaceuticals
NRXP stock →NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Tonix Pharmaceuticals
TNXP stock →Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia.
Health Care · Biotechnology: Pharmaceutical Preparations · 142 employees
NRXP vs TNXP FAQ
Which is bigger, NRX Pharmaceuticals or Tonix Pharmaceuticals?
Tonix Pharmaceuticals (TNXP) is larger, with a market capitalization of $125.37M compared with $122.53M for NRX Pharmaceuticals (NRXP).
Which stock has performed better over the past year, NRXP or TNXP?
NRXP returned -19.27% over the past 12 months, compared with -67.63% for TNXP (price return, excluding dividends). Past performance does not predict future results.
Are NRX Pharmaceuticals and Tonix Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.